[ad_1]
Dublin, December 13, 2021 (Global News Agency) – “The liquid biopsy market is classified by product (test kits, instruments, services), circulating biomarkers (CTC, ctDNA), technology (NGS, PCR), application (cancer (lung cancer, breast cancer, prostate), non-cancer), final Users (reference laboratories, hospitals)-global forecast to 2026” Report has been added to ResearchAndMarkets.com supply.
The global liquid biopsy market is expected to increase from USD 2.5 billion in 2021 to USD 5.8 billion in 2026, with a compound annual growth rate of 18.1% during the forecast period.
Market dynamics
- driver
- Incidence and prevalence of cancer are rising
- Initiatives carried out by the Global Health Organization to raise awareness of cancer
- Increasing preference for non-invasive treatment procedures
- constraint
- Some liquid biopsies are less sensitive
- Chance
- Companion diagnosis is becoming more and more important
- Growth opportunities in emerging countries
- challenge
- Unclear reimbursement scenarios
During the forecast period, broken down by product and service, the growth rate of test kits in the liquid biopsy market is the highest
The liquid biopsy market is divided into test kits, instruments and services based on products and services. In 2020, the growth rate of the detection kit part in the liquid biopsy market is the highest. Wide availability…
The full story can be found on Benzinga.com
[ad_2]
Source link
